- Home
- QNCX vs PYXS Comparison
QNCX vs PYXS Comparison
Compare QNCX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- PYXS
- Stock Information
- Founded
- QNCX 2012
- PYXS 2018
- Country
- QNCX United States
- PYXS United States
- Employees
- QNCX N/A
- PYXS N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- PYXS Health Care
- Exchange
- QNCX Nasdaq
- PYXS Nasdaq
- Market Cap
- QNCX 85.9M
- PYXS 79.4M
- IPO Year
- QNCX 2019
- PYXS 2021
- Fundamental
- Price
- QNCX $1.65
- PYXS $2.57
- Analyst Decision
- QNCX Strong Buy
- PYXS Strong Buy
- Analyst Count
- QNCX 6
- PYXS 5
- Target Price
- QNCX $8.00
- PYXS $7.75
- AVG Volume (30 Days)
- QNCX 263.4K
- PYXS 763.0K
- Earning Date
- QNCX 11-12-2025
- PYXS 11-11-2025
- Dividend Yield
- QNCX N/A
- PYXS N/A
- EPS Growth
- QNCX N/A
- PYXS N/A
- EPS
- QNCX N/A
- PYXS N/A
- Revenue
- QNCX N/A
- PYXS $2,820,000.00
- Revenue This Year
- QNCX N/A
- PYXS N/A
- Revenue Next Year
- QNCX N/A
- PYXS N/A
- P/E Ratio
- QNCX N/A
- PYXS N/A
- Revenue Growth
- QNCX N/A
- PYXS N/A
- 52 Week Low
- QNCX $0.69
- PYXS $0.83
- 52 Week High
- QNCX $2.45
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- QNCX 56.09
- PYXS 76.83
- Support Level
- QNCX $1.59
- PYXS $2.10
- Resistance Level
- QNCX $1.68
- PYXS $2.35
- Average True Range (ATR)
- QNCX 0.06
- PYXS 0.17
- MACD
- QNCX 0.01
- PYXS 0.00
- Stochastic Oscillator
- QNCX 69.57
- PYXS 98.51
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.